Leukotrienes (LTs) are arachidonic acid-derived lipid mediators involved in the pathogenesis and progression of diverse inflammatory disorders. The cysteinyl-leukotrienes LTC 4 , LTD 4 , and LTE 4 are important mediators of asthma, and LTB 4 has recently been implicated in atherosclerosis. Here we report that mRNA levels for the three key enzymes/proteins in the biosynthesis of cysteinyl-leukotrienes, 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), and LTC 4 synthase (LTC 4 S), are significantly increased in the wall of human abdominal aortic aneurysms (AAAs). In contrast, mRNA levels of LTA 4 hydrolase, the enzyme responsible for the biosynthesis of LTB 4 , are not increased. Immunohistochemical staining of AAA wall revealed focal expression of 5-LO, FLAP, and LTC 4 S proteins in the media and adventitia, localized in areas rich in inflammatory cells, including macrophages, neutrophils, and mast cells. Human AAA wall tissue converts arachidonic acid and the unstable epoxide LTA 4 into significant amounts of cysteinyl-leukotrienes and to a lesser extent LTB 4 . Furthermore, challenge of AAA wall tissue with exogenous LTD 4 increases the release of matrix metalloproteinase (MMP) 2 and 9, and selective inhibition of the CysLT1 receptor by montelukast blocks this effect. The increased expression of LTC 4 S, together with the predominant formation of cysteinyl-leukotrienes and effects on MMPs production, suggests a mechanism by which LTs may promote matrix degradation in the AAA wall and identify the components of the cysteinyl-leukotriene pathway as potential targets for prevention and treatment of AAA.
Leukotrienes (LTs) are arachidonic acid-derived lipid mediators involved in the pathogenesis and progression of diverse inflammatory disorders. The cysteinyl-leukotrienes LTC 4 , LTD 4 , and LTE 4 are important mediators of asthma, and LTB 4 has recently been implicated in atherosclerosis. Here we report that mRNA levels for the three key enzymes/proteins in the biosynthesis of cysteinyl-leukotrienes, 5-lipoxygenase (5-LO), 5-LO-activating protein (FLAP), and LTC 4 synthase (LTC 4 S), are significantly increased in the wall of human abdominal aortic aneurysms (AAAs). In contrast, mRNA levels of LTA 4 hydrolase, the enzyme responsible for the biosynthesis of LTB 4 , are not increased. Immunohistochemical staining of AAA wall revealed focal expression of 5-LO, FLAP, and LTC 4 S proteins in the media and adventitia, localized in areas rich in inflammatory cells, including macrophages, neutrophils, and mast cells. Human AAA wall tissue converts arachidonic acid and the unstable epoxide LTA 4 into significant amounts of cysteinyl-leukotrienes and to a lesser extent LTB 4 . Furthermore, challenge of AAA wall tissue with exogenous LTD 4 increases the release of matrix metalloproteinase (MMP) 2 and 9, and selective inhibition of the CysLT1 receptor by montelukast blocks this effect. The increased expression of LTC 4 S, together with the predominant formation of cysteinyl-leukotrienes and effects on MMPs production, suggests a mechanism by which LTs may promote matrix degradation in the AAA wall and identify the components of the cysteinyl-leukotriene pathway as potential targets for prevention and treatment of AAA. cardiovascular disease | eicosanoid | inflammation L eukotrienes (LTs) are powerful lipid mediators released by inflammatory cells, such as macrophages, neutrophils, eosinophils, and mast cells (1, 2) . In cellular biosynthesis of LTs, arachidonic acid is oxygenated by 5-lipoxygenase (5-LO) into the unstable epoxide LTA 4 with the aid of the accessory 5-LO activating protein (FLAP). Here, the pathway branches. The LTA 4 hydrolase (LTA 4 H) can metabolize LTA 4 to LTB 4 , which acts as a potent chemoattractant. Alternatively, LTA 4 can be conjugated with glutathione by LTC 4 synthase (LTC 4 S) to form cysteinylleukotrienes LTC 4 , LTD 4 , and LTE 4 (cysLTs), which promote airway smooth-muscle constriction and increased vascular permeability. LTB 4 and cysLTs exert biological effects through two pairs of G protein-coupled receptors denoted BLT1/BLT2 and CysLT1/CysLT2, respectively (3) (4) (5) (6) . LTs and their receptors exert diverse functions in immune and inflammatory responses and have been associated with many diseases, in particular asthma (7) .
Abdominal aortic aneurysm (AAA) is a cardiovascular disease associated with aging, whereby chronic inflammation in the aortic wall and proteinase-mediated degradation of structural matrix proteins are believed to contribute to its development and rupture (8, 9) . Inflammatory cells such as macrophages, neutrophils, and mast cells have been shown to be sources of proteolytic enzymes in the AAA wall (10) . Moreover, several studies have pointed to the intraluminal thrombus as a site of proteolytic activity (11, 12) and source of chemotactic factors (13, 14) , potentially influencing the structural and cellular composition of the AAA wall (15) . LTs have been the subject of recent investigations indicating an important role for those lipid mediators in cardiovascular diseases. Thus, genetic, morphological, biochemical, pharmacological, and functional evidence collected from human and animal studies have implicated LTs, in particular LTB 4 , in the development and progression of atherosclerosis (16, 17) and as risk factors in human myocardial infarction (18) . Less is known regarding LTs and AAA, and studies using animal models have yielded conflicting results about the involvement of the 5-LO pathway in aneurysmal disease (19) (20) (21) . In the present study we examined the expression of 5-LO cascade-related enzymes in human AAA. Biochemical analysis revealed an overexpression of 5-LO, FLAP, and LTC 4 S, but not of LTA 4 H, in the AAA wall. Using immunohistochemistry, we also found that these three enzymes, required for cysLT biosynthesis, are expressed in the media and adventitia layers of the AAA wall and colocalize with the presence of inflammatory cells, in particular macrophages and mast cells. Moreover, this enzymatic machinery is catalytically active and capable of converting arachidonic acid into LTs. Finally we show that LTD 4 induces metalloproteinases in a CysLT receptor-dependent manner, suggesting a mechanism by which these mediators may promote arterial wall degradation and development of AAA.
Results
Expression of 5-LO, FLAP, and LTC 4 S mRNA in Human AAA. In human AAA wall we found increased transcript levels of 5-LO, FLAP, and LTC 4 S compared with control aortas, corresponding to 2.5-fold (2.46 ± 0.26, P = 0.002), 1.5-fold (1.51 ± 0.09, P = 0.0012), and 1.5-fold (1.81 ± 0.21, P = 0.0068) increases, respectively (Fig.  1) . In contrast, the levels of LTA 4 H mRNA in AAA wall were not significantly different when compared with control ( Fig. 1) . presence of CD68-and CD66b-positive cells, reflecting the presence of macrophages and neutrophils, respectively ( Fig. 2A) . In the same area it was also possible to see the presence of T lymphocytes, as shown by CD3-positive staining ( Fig. 2A) .
In the adventitia, once again, there were also plenty of 5-LOand LTC 4 S-positive cells that colocalize with CD68 (macrophages) and CD66b (neutrophils) (Fig. 2B) . Moreover, in the adventitia, it was also possible to detect the presence of mast cells in the same area, as determined by tryptase staining (Fig. 2B) .
We also carried out immunohistochemistry of AAA thrombus. The abluminal side did not show the presence of cells, confirming previous observations that this part of thrombus is mainly composed of densely packed fibrin (22) . In contrast, the luminal side of the thrombus showed the presence of focal accumulations of inflammatory cells, in particular macrophages and neutrophils, that colocalized with cells positive for 5-LO and LTC 4 S (Fig. 3) .
Immunohistochemical staining of LTA 4 H in AAA tissue showed the presence of LTA 4 H in the media layer ( Fig. S1A ), adventitia layer (Fig. S1B) , and luminal thrombus (Fig. S1C) , indicating that the branch of 5-LO pathway responsible for LTB 4 biosynthesis is also present.
Biosynthesis of LTs.
Homogenates of human aortic tissue from AAA surgery were used to study the metabolism of arachidonic acid. Incubations of AAA wall tissue with arachidonic acid produced significant amounts of cysLTs (2.62 ± 0.61 ng/μg of protein) when compared with LTB 4 production (1.25 ± 0.51 ng/μg of protein) (Fig. 4) , as assessed by reverse-phase HPLC coupled to enzyme immunoassay (EIA). Similarly, more cysLTs (2.15 ± 0.97 ng/μg of protein) than LTB 4 (1.02 ± 0.50 ng/μg of protein) were produced in the thrombus, although the differences did not reach statistical significance (Fig. 4) .
In selected experiments we directly assessed the LTA 4 H and LTC 4 S activities by incubations of subcellular fractions with the unstable epoxide LTA 4 . To do that, we isolated (by ultracentrifugation) cytosolic (rich in LTA 4 H) and membrane (rich in LTC 4 S) fractions from AAA wall and incubated them with LTA 4 (10 μM). HPLC quantification showed a 2-fold higher formation of LTC 4 (2.14 pmol/μg protein; Fig. S2A (19, 23) , such as MMP-9 and MMP-2, and the presence of these proteinases has been associated with degradation of connective tissue (9) . Therefore, we examined the potential role of LTD 4 as a stimulus for the release of MMPs from AAA tissue.
Gelatin gel zymography showed an increased level of MMP-2 and its proform when AAA wall was incubated with LTD 4 (10 μM) as compared with the control group (Fig. 6 A and B) . Moreover, pretreatment of AAA tissue with the selective CysLT1 antagonist montelukast (1 μM) reduced the MMP signals to control levels ( Fig. 6 A and B) .
Discussion
LTs are paracrine lipid mediators that have potent proinflammatory biological activities. One class of LTs, the cysLTs, are well recognized as important signaling molecules in human asthma, and leukotriene-modifying drugs have been produced for this application (24) . However, more recent studies have strongly implicated LTs as mediators of vascular inflammation, and in most cases LTB 4 was identified as the culprit. Consequently, a role for the LTB 4 arm of the 5-LO pathway, including FLAP, LTA 4 H, and BLT1, in cardiovascular diseases is currently in the focus of intense research efforts, both within academia and industry (16, 25) .
AAA is a vascular pathology characterized by weakening of the medial elastic lamina layer and infiltration of media and adventitia by immune cells, such as macrophages and T cells, which release a variety of chemokines and other mediators that can enhance degradation of the extracellular matrix (10) . The most known and studied mediators involved in aortic wall degeneration are MMPs, and several investigations have indicated a pivotal role for MMPs in the pathological process leading to AAA growth and rupture (26) . Furthermore, it has been suggested that the presence of intraluminal thrombus could affect the structural and cellular composition of the underlying vessel wall (15) and sustain the proteolytic activity by releasing MMPs (11) .
Thus far, only a limited number of animal studies have addressed the potential role of LTs in AAA, yielding different results. Funk and coworkers found a protective effect of 5-LO (19) . In a later study, the same authors failed to detect a role for 5-LO in the angiotensin II-induced AAA model in the ApoEdeficient mouse (21) . On the other hand, other investigators found that genetic deletion or pharmacological inhibition of the BLT1 receptor afforded significant protection against AngII-induced AAA (20, 27) . In line with the latter observations, Houard et al. (14) recently proposed a role for LTB 4 , derived from neutrophils within the intraluminal thrombus, as a chemotactic factor in AAA.
In the present study we used a collection of fresh AAA specimens obtained from patients undergoing elective surgery for repair of infrarenal aneurysms, to assess the expression profile and activity of enzymes in the 5-LO pathway. Surprisingly, we found that cysLTs, rather than LTB 4 , may be involved in human AAA. Analysis of 28 patients revealed a striking increase in the expression of 5-LO mRNA. In addition, we found significant increases in the mRNA levels of FLAP and LTC 4 S (Fig. 1) , thus completing the triplet of key proteins required for cysLTs biosynthesis. In contrast, LTA 4 H did not display significantly elevated levels of mRNA, demonstrating an important difference between human AAA and human atherosclerosis, in which LTA 4 H is up-regulated and has been shown to correlate with symptoms of plaque instability (17) .
LT-Synthesizing Enzymes Are Present in Media and Adventitia Layers
at Sites Rich in Inflammatory Cells. By immunostaining it was possible to detect the presence of proteins of the whole LT enzymatic pathway in several segments of the AAA wall. Thus, the media layer presented focal accumulations of 5-LO-, FLAP-, LTA 4 H-, and LTC 4 S-positive cells. The same areas also stained positively for CD68, indicating that macrophages could be the main source of LTs and confirming previous results obtained in animal models (19, 28) . Moreover, in agreement with previous studies demonstrating the presence of different types of immune cells in AAA (10, 13, 15), we could detect CD66b-and CD3-positive cells, markers of human neutrophils and T lymphocytes, respectively, and these cells clustered together with macrophages.
Going deeper into the AAA wall, through the adventitia layer, immunostaining showed a pattern similar to the one observed in the media, with presence of focal accumulations of inflammatory cells, mostly macrophages and neutrophils, which are positive for 5-LO, FLAP, LTC 4 S, and LTA 4 H. However, in the adventitia, cells staining strongly for tryptase were also detected, indicating the presence of mast cells that are known to be involved in the early and late phases of inflammatory reactions by release of chemokines, cytokines, and lipid mediators, such as cysLTs (29) .
AAA Wall Converts Arachidonic Acid Primarily into cysLTs. Next, we assessed whether our mRNA and morphological data correlated with differences in enzyme activities. Thus, we incubated homogenized human AAA wall tissue with arachidonic acid and analyzed the formation of LTs to probe the entire 5-LO pathway machinery. Tandem HPLC/EIA analysis revealed a significantly increased ability of the wall to convert arachidonic acid into cysLTs and lesser amounts of LTB 4 , in accord with the results 4 and LTB 4 in human AAA. The AAA wall and the thrombus (n = 8) were homogenized at 100,000 × g for 1 h at 4°C. The cytosolic fraction (supernatant) and the membrane fraction (pellet) were incubated with 10 μM of LTA 4 . LTC 4 and LTB 4 were measured by tandem HPLC/ EIA, and data are presented as media ± SEM. *P < 0.05. obtained by real-time PCR (Fig. 1) . These data indicated a greater LTC 4 S activity as compared with LTA 4 H activity. (Fig. 5 and Fig. S2) . Although large amounts of LTs could be detected in certain experiments (Fig. S2) 4 . In fact, further activity measurements, including incubations of thrombus with both arachidonic acid and LTA 4 , revealed a predominant production of cysLTs that in the latter case reached statistical significance (Fig. 5) .
Challenge with LTD 4 Increases Release of MMP-2 from AAA Wall
Tissue. Production of cysLTs in the vascular wall may have several effects that potentially could promote inflammation and aneurysm formation. For instance, MMPs have been implicated in the pathogenesis of aortic aneurysm (8, 9) , and a recent study showed that reduced formation of AAA in 5-LO knockout mice is associated with a decrease in aortic MMP-2 activity (19) . Along these lines, we show that challenge of human AAA wall tissue with LTD 4 induces a significant increase of proMMP-2 and MMP-2 levels that potentially could contribute to matrix degradation in the vessel wall. This effect seems to be mediated via CysLT1 receptors, because montelukast, a selective CysLT1 antagonist, could block the increased release of MMP-2 (Fig. 6 ).
In addition to increased MMP activity, previous studies have shown that cysLTs and their receptors, in particular CysLT1, are involved in de novo expression and secretion of several proinflammatory cytokines, such as IL-5, macrophage inflammatory protein-1α and -β, as well as TNF-α from macrophages and mast cells (30) (31) (32) . These activities of cysLTs are believed to be involved in the amplification of innate as well as adaptative immune responses.
Anti-LTs as Potential Drugs Against AAA. Assuming that production of cysLTs occurs during the course of AAA development, it should be possible to pharmacologically block its synthesis and actions with already-existing anti-LT drugs. Inhibition of 5-LO or FLAP would block synthesis of all LTs, as well as antiinflammatory lipoxins. Selective inhibition of LTC 4 S, on the other hand, could block synthesis of cysLTs, while potentially sparing lipoxin biosynthesis, as previously demonstrated for a selective inhibitor of LTA 4 H (33, 34) . This approach may also be advantageous, given the steadily increasing number and complex crossregulations reported for cysLT receptors (35) (36) (37) . Finally, on the basis of the results of the present study, an obvious approach would be to use established antiasthma drugs, such as montelukast or similar CysLT1 antagonists, for treatment of AAA, a possibility that should be straightforward to test in a clinical trial.
Materials and Methods
Sample Collection. Patients (n = 28) who were about to undergo elective surgery for infrarenal AAA were selected for the study. Tissue was taken from the anterior or lateral wall, because tissue sampling from the posterior wall was considered to add to the risk of surgery. Control ascending aorta samples for RNA studies were obtained from eight organ donors without clinical or macroscopic signs of aortic atherosclerosis at University Central Hospital, Helsinki, Finland. The use of organ donor tissues was approved by The National Authority for Medicolegal Affairs of Finland.
AAA samples were immediately fixed in 4% formaldehyde for light microscopy or snap-frozen in liquid nitrogen for RNA isolation. All of the procedures were approved by the local ethics committees, and all of the patients gave written informed consent.
Real-Time PCR. Total RNA from frozen samples was isolated with TRIzol (BRLLife Technologies) and an RNEasy Mini Kit (Qiagen) after homogenization using FastPrep (MP Biomedicals) according to the manufacturer's instructions. The quality of RNA was analyzed with an Agilent 2100 bioanalyzer (Agilent Technologies) and quantity assessed by a NanoDrop. cDNA was synthesized from total RNA by using SuperScript II reverse transcriptase (Invitrogen), and 2 μl of cDNA were amplified by real-time PCR performed in a TaqMan 7300 instrument (Applied Biosystems). Normalization was made to cyclophilin A. The following primer/probe pairs were obtained by Assay-on-Demand (Applied Biosystems): 5-LO, FLAP, LTA 4 H, and LTC 4 S, with assay IDs Hs00386528_m1, Hs00233463_m1, Hs00168505_m1, and Hs00168529_m1, respectively. The PCR amplification was related to a standard curve.
Immunohistochemistry. Paraffin sections were cleared in xylene, rehydrated in graded ethanol (100-70%), and subjected to antigen retrieval by boiling in DIVA buffer (Biocare Medical) for 20 min. After cooling to room temperature in water, sections were incubated in 3% hydrogen peroxide (H 2 O 2 ) for 5 min to inhibit endogenous peroxidase activity. The specimens were then rinsed three times for 5 min each in PBS, blocked for 30 min in PBS with normal goat serum (1:5), and incubated overnight at 4°C in a humidified chamber with and without primary antibodies against human 5-LO (a gift from Olof Rådmark, Karolinska Institutet, Stockholm, Sweden), human FLAP (a gift from Jilly Evans, Amira Pharmaceuticals, San Diego, CA), human LTA 4 H and LTC 4 S (prepared in house), human CD68 (Dako), human CD66b (Fitzgerald Industries), human CD3 (Santa Cruz Biotechnology), and Tryptase (Dako). The samples were then rinsed in PBS and incubated with biotinylated secondary antibody (1:1,500) for 1 h at room temperature followed by avidin-biotin amplification (ABC Elite) for 30 min, and developed with 3,3′-diaminobenzidine (Sigma). Sections were counterstained with Mayer's hematoxylin for 1 min and mounted. Negative controls were obtained by substituting the primary antibodies with PBS.
Reverse-Phase HPLC Coupled to EIA. Human AAA (n = 9) were collected immediately after surgery, dissected, weighed, homogenized in 0.1 M PBS (pH 7.8) containing proteinase inhibitor mixture (Roche) and EDTA (1 mM), and sonicated three times for 10 s on ice. Homogenates were incubated with 1 mM ATP, 2 mM Ca 2+ , and 40 μM arachidonic acid for 10 min at room temperature. The reaction was stopped by adding two volumes of cold methanol. Samples were centrifuged at 10,000 × g for 10 min at 4°C, and the resulting supernatants were acidified to pH 3-4 and 5.6 for LTB 4 or cysLTs, respectively. Samples were purified by solid-phase extraction (Supelco LC18) and analyzed by reverse-phase HPLC. The column (Nova-Pak C18; Waters) was eluted with acetonitrile/methanol/water/acetic acid (30:35:35:0.01 by volume) at 0.8 mL/ min, and absorbance was monitored at 270 nm or 280 nm for LTB 4 and cysLTs, respectively. Fractions corresponding to the retention times of LTB 4 , LTC 4 , LTD 4 , and LTE 4 standards (Cayman Chemical) were collected, dried under nitrogen, and resuspended with EIA buffer. Levels of LTB 4 or cysLTs were determined in duplicate assays with an LTB 4 or cysLT EIA kit (Cayman Chemical) by using dilutions within the linear portion of the standard curves.
In selected experiments (n = 8), AAA wall tissue was homogenized in PBS (pH 7.4) 1:3/wt/vol and then centrifuged at 100,000 × g for 60 min at 4°C to prepare cytosolic (supernatant) and membrane (pellet) fractions. The cytosolic fraction was incubated with 10 μM LTA 4 (Cayman Chemical) and 0.2% BSA for 10 min at room temperature, and the pellet was resuspended in PBS (initial volume) and incubated with 10 μM LTA 4 , 5 mM glutathione, and 0.2% BSA for 10 min at room temperature. The reaction was stopped with two volumes of cold methanol. Samples were purified, extracted, and analyzed by HPLC as described above.
MMP Assays and Gel Zymography. The aneurysm walls from selected surgeries (n = 4) were cut into pieces of ≈1 mm 3 and divided equally into three separate samples. They were incubated in RPMI medium 1640 (Sigma) with LTD 4 (10 μM) with or without pretreatment with montelukast (Cayman Chemical; 1 μM, 30 min at 37°C) for 24 h at 37°C (2 mL/g wet tissue), as previously described (12, 14) . The conditioned media containing the released material were collected and stored at −80°C until use.
Zymography supplies were purchased from Invitrogen. ProMMP-2, MMP-2, proMMP-9, and active MMP-9 distributions were determined from conditioned media. Gelatin substrate zymograms were prepared using precast 10% SDSpolyacrylamide gels containing 1 mg/mL of gelatin. Equal volumes of experimental media samples were diluted into 2× Tris-glycine SDS sample buffer and electrophoretically separated under nonreducing conditions. Proteins were incubated in renaturating buffer (Invitrogen) for 30 min at room temperature. The gels were incubated overnight at 37°C in developing buffer (Invitrogen). After 1 h staining with Coomassie brilliant blue and destaining for 2 d with 10% acetic acid and 40% methanol in water, gelatinase activity was evident by clear bands against a dark blue background. Quantification of the bands was performed using digital camera Fujifilm LAS-1000 and densitometry software ImageJ. 
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